Bristol Myers Squibb CoUSD 2.00 Cum.Conv News

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

13.01.25	Like Bristol-Myers Squibb And AbbVie, Johnson & Johnson Seeks To Bolster Neuropsychiatric Portfolio With $15 Billion Deal (Benzinga)
02.12.24	Is Bristol-Myers Squibb Stock a Millionaire Maker? (MotleyFool)
24.11.24	Where Will Bristol Myers Squibb Be in 5 Years? (MotleyFool)
21.11.24	Is Bristol Myers Squibb Stock a Buy? (MotleyFool)
12.11.24	This Bristol-Myers Squibb Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday (Benzinga)
11.11.24	What's Going On With Bristol-Myers Squibb Shares Monday? (Benzinga)
08.11.24	Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks (Benzinga)
01.11.24	Bristol Myers Squibb Expects New Schizophrenia Treatment To Boost Long-Term Growth, Analysts Remain Cautious (Benzinga)
31.10.24	Bristol Myers Squibb (BMY) Q3 2024 Earnings Call Transcript (MotleyFool)
31.10.24	Bristol Myers Squibb Boosts 2024 Outlook On Strong Demand For Blood Thinner Med, New Drugs Drive Q3 Profit (Benzinga)
23.10.24	Unpacking the Latest Options Trading Trends in Bristol-Myers Squibb (Benzinga)
07.10.24	Unveiling 11 Analyst Insights On Bristol-Myers Squibb (Benzinga)
01.10.24	This Is What Whales Are Betting On Bristol-Myers Squibb (Benzinga)
30.09.24	Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline (Benzinga)
27.09.24	Bristol-Myers Squibb stock jumps on schizophrenia drug approval (MarketWatch)
18.09.24	Bristol Myers Squibb Presents Data For Multiple Sclerosis Drug Zeposia, Shows Long-Term Efficacy (Benzinga)
16.09.24	What Analysts Are Saying About Bristol-Myers Squibb Stock (Benzinga)
02.09.24	2 Reasons Bristol Myers Squibb Stock Could Be a Bargain, Down 34% From Its All-Time High (MotleyFool)
22.08.24	Key Takeaways From Bristol-Myers Squibb Analyst Ratings (Benzinga)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Holcim	91.22	1.56 %	K V
Sonova Hldg	319.70	1.56 %	K V
Lonza Grp	591.00	1.34 %	K V
Sika	231.50	1.27 %	K V
CieFinRichemont	171.70	0.94 %	K V
Swiss Re	138.05	-0.40 %	K V
Zurich Insur Gr	537.20	-0.52 %	K V
Kuehne+Nagel Int	204.60	-0.97 %	K V
Part Grp Hldg	1’389.50	-1.03 %	K V
Givaudan	3’818.00	-3.12 %	K V